Group 1 - The Hong Kong General Chamber of Commerce met with the Deputy Financial Secretary to discuss the upcoming Policy Address and presented a proposal to strengthen Hong Kong's international status and business environment amid geopolitical changes and economic uncertainty [1] - The Chamber proposed a three-phase strategy: immediate actions to build confidence, accelerating smart city transformation as a mid-term goal, and establishing resilience in the long term [1] - According to the Chamber's recently released "Asian Cities Internationalization Index," Hong Kong ranks as the most internationalized major city in Asia, which can help attract more international organizations and key enterprises to the city [1] Group 2 - The Chamber emphasized the importance of nurturing local talent to meet the demands of a rapidly evolving economy while also attracting global talent [1] - It highlighted the need for Hong Kong to accelerate digital innovation and invest in emerging industries such as artificial intelligence and low-altitude economy to enhance efficiency across various sectors [1] - Another major recommendation includes implementing effective environmental policies to improve both environmental and economic performance, which will support population growth and attract local and international talent [2] Group 3 - The Chamber expressed appreciation for the government's commitment to improving governance and supporting efforts to enhance confidence and certainty in Hong Kong [3]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 本公告乃由本公司自願作出。 董事會欣然宣佈，於二零二五年六月三十日（聯交所交易時段後），本公司（作 為買方）已與賣方及Conflux訂立諒解備忘錄，內容有關收購目標公司全部股 權的潛在收購事項，前提為目標公司按照與本公司的協議完成收購Conflux 資產。 潛在收購事項須待本公司與賣方訂立正式協議後方可作實。因此，潛在收 購事項未必會進行。本公司將根據上市規則適時刊發公告。股東及本公司 潛在投資者於買賣本公司股份時務請審慎行事。 – 1 – INNOVATIVE PHARMACEUTICAL BIOTECH LIMITED 領航醫藥及生物科技有限公 司 （於開曼群島註冊成立並於百慕達存續之有限公 司） （股份代 號：399） 自願公告 有關潛在收購事項的 諒解備忘錄 緒言 董事會欣然宣佈，於二零二五年六月三十日（聯交所交易時段後），本公司（作 為買方）已與賣方及Conflux訂立諒解備忘錄，內容有關潛在 ...